Search Results
Your search for it matches 16118 pages
Showing 1901 - 195023andMe Granted FDA 510(k) Clearance to Report Additional BRCA Variants
23andMe has announced that the company has received a U.S. Food and Drug Administration (FDA) 510(k) clearance to expand its existing BRCA1/BRCA2 (Selected Variants) Genetic Health Risk Report. The clearance allows 23andMe to report an additional 41 variants in the BRCA1 and BRCA2 genes known to be ...
Risk Factors for Melanoma Among Individuals Living in Atlantic Canada
Investigators in Canada may have uncovered the factors contributing to the higher risk of melanoma among individuals living in Atlantic regions, according to a recent study published by Lagacé et al in Cancers. These findings may provide insights into effective strategies for skin cancer...
Time Gaps May Be Critical Parameters When Sparing Skin During FLASH Radiation Therapy
Researchers have demonstrated that, in preclinical models, multiple beams and intervals in delivery during FLASH radiation therapy may compromise the skin-sparing effects of the technique, according to a novel study published by Mascia et al in the International Journal of Radiation Oncology •...
Are Cannabinoids Safe and Effective for Reducing Symptoms in Pediatric Patients With Cancer?
Investigators have revealed that there may be a lack of evidence to inform the dosing, safety, and efficacy of cannabinoids for managing symptoms in pediatric patients with cancer, according to a recent systematic review and meta-analysis published by Chhabra et al in Cancer. Background Although...
Role of HER2 Expression in Hormone Receptor–Positive Metastatic Breast Cancer
This is Part 2 of Novel Therapies for Advanced Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Aditya Bardia, Sara Tolaney, and Antonio C. Wolff discuss the role of HER2 expression in hormone receptor–positive...
How Guideline-Concordant Are Cancer Treatment Recommendations From ChatGPT?
Researchers have found that about one-third of treatment recommendations from the artificial intelligence (AI) model ChatGPT 3.5 were nonconcordant with the NCCN Clinical Practice Guidelines in Oncology® (NCCN Guidelines®), according to a recent study published by Chen et al in JAMA Oncology. The...
Rural Patients With Cancer: Receipt of Surgical Care at High- vs Low-Volume Hospitals
Patients with cancer who live in rural Pennsylvania counties appear to know that they may have better outcomes if they receive their cancer surgery at a hospital that performs a high volume of those procedures—but many still opt for lower-volume hospitals closer to home when their cancer is likely...
Short-Term Use of Immunosuppressants May Not Be Linked to Increased Cancer Risk in Patients With Ocular Inflammatory Diseases
Short-term use of immunosuppressants in patients with ocular inflammatory disease may not be associated with an increased risk of developing cancer, according to a recent study published by Buchanich et al in BMJ Oncology. Background The Systemic Immunosuppressive Therapy for Eye Diseases (SITE)...
The Future Priorities of the National Cancer Institute
Fifty-two years ago, President Richard Nixon signed the National Cancer Act of 1971 into law, which established the National Cancer Institute (NCI) in its current form. At the time, the budget was $1.6 billion. Today, it is $7.8 billion, $4.5 billion less than the amount needed to keep up with...
Modified Citrus Pectin Treatment for Nonmetastatic Prostate Cancer
In the long-term treatment phase of an Israeli phase II study reported in the journal Nutrients, Keizman et al found that PectaSol modified citrus pectin (P-MCP) may be effective in patients with nonmetastatic, biochemically relapsed prostate cancer. As stated by the investigators, “[P-MCP] is a...
Novel Targeted Therapy Combination May Be an Effective First-Line Option for Gastric or Gastroesophageal Junction Adenocarcinoma
Researchers have found that the novel targeted therapy zolbetuximab in combination with a standard chemotherapy may extend survival in patients with advanced gastric or gastroesophageal junction adenocarcinoma and overexpression of the claudin-18 isoform 2 protein (CLDN18.2), according to a novel...
Sacituzumab Govitecan-hziy Continues to Show Benefit in Patients With Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
The antibody-drug conjugate sacituzumab govitecan-hziy continued to demonstrate superior benefit for patients with hormone receptor–positive, HER2-negative metastatic breast cancer when compared with standard chemotherapy, according to the final analysis of the phase III TROPiCS-02 study published...
Crystal S. Denlinger, MD, FACP, Named New Chief Executive Officer of NCCN
On August 23, 2023, the National Comprehensive Cancer Network® (NCCN) announced Crystal S. Denlinger, MD, FACP, as incoming Chief Executive Officer (CEO). Dr. Denlinger, who is currently Senior Vice President and Chief Scientific Officer of NCCN, will lead the global guidelines organization...
Bariatric Surgery and Cancer Incidence and Mortality for Patients With Severe Obesity
Investigators have demonstrated that bariatric surgery may be associated with a lower incidence of all-cancer and obesity-related cancer among female patients, according to a recent study published by Adams et al in Obesity. The new findings also suggested cancer mortality was significantly reduced ...
Developing Solutions for Cancer Care Disparities Across Geography
Understanding the complexities of health disparities within cancer care requires an exploration beyond immediate clinical factors. According to Elisa Rodriguez, PhD, MS, of Roswell Park Comprehensive Cancer Center, Buffalo, New York, geography plays a critical role in defining health outcomes in...
More on the Complexity of Prior Authorization
We read with interest the recent commentary by S. Monica Soni, MD, and Andrew A. Hertler, MD, FACP, on prior authorization (June 10, 2023, issue of The ASCO Post). The nuances of prior authorization in our health-care landscape are both complex and consequential. Conceived as a safeguard against...
How the Cancer Moonshot Aims to Improve the Quality of Life for Adolescent and Young Adult Cancer Survivors
Several recent studies have shown an increasingly disturbing trend: the incidence of early-onset cancers—those diagnosed in individuals younger than age 50—is on the rise, and not just in the United States but globally as well. Worldwide, in 2019, there were a reported 1.19 million new cases of...
Rapid Guideline Update Offers Key Evidence-Based Recommendations for Stage III NSCLC Management
A new ASCO guideline rapid update provides updated recommendations for the management of stage III non–small cell lung cancer (NSCLC). These updated recommendations made by the ASCO expert panel cover treatment options for patients with resected disease and specific genetic mutations as well as...
Unraveling the Mechanisms Behind the Antichemotherapy Effects of ABCG2 Proteins
Researchers may have discovered how to prevent the cellular-cleaning protein ABCG2 from removing chemotherapeutics from tumor cells, according to a recent study published by Gose et al in Nature Communications. These research findings may improve future cancer therapeutics. Background Most new...
Are All Benzodiazepines Created Equal in Terms of Survival in Patients With Pancreatic Cancer?
Patients with pancreatic cancer who were treated with the benzodiazepine lorazepam had shorter progression-free survival periods than patients who were not, according to study results published by Cornwell et al in Clinical Cancer Research. In contrast, patients who were treated with the...
Researchers May Have Identified Several New Breast Cancer Susceptibility Genes
Researchers have identified genes that may be associated with breast cancer and could eventually be included in tests to identify high-risk patients, according to a recent study published by Wilcox et al in Nature Genetics. Background Currently, genetic tests for breast cancer consider a few genes...
ARTISTRY-7 and ROSELLA: Phase III Trials to Evaluate Novel Agents in Platinum-Resistant Ovarian Cancer
Platinum resistance occurs in almost all patients whose ovarian cancer recurs. Single-agent chemotherapies are commonly used in this setting, but outcomes are generally poor, leaving a large unmet need for effective treatment. At the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on...
Is Chemotherapy Shortage Setting Back Clinical Trials?
“Any protocol that involves cisplatin or carboplatin as part of a study is on hold because of the chemotherapy shortage,” Mark J. Ratain, MD, FASCO, Chief Hospital Pharmacologist, University of Chicago Medicine, said in an interview with The ASCO Post. “Many times, our clinical trials are building...
Chemotherapy Shortage Impacts Patients, Physicians, Costs, and Clinical Trials
Grim, grimmer, and grinding are among the terms reported in the press to describe the current chemotherapy shortage.1,2 And, “it is not going away,” Mark J. Ratain, MD, FASCO, Chief Hospital Pharmacologist, University of Chicago Medicine, told The ASCO Post. “This is a progressive problem like...
New Challenge in Triple-Negative Breast Cancer: Optimizing the Sequencing of Treatments
New approaches are offering hope for better outcomes in metastatic triple-negative breast cancer, according to Suchita Pakkala, MD, of Emory University’s Winship Cancer Institute, Atlanta. She shared her thoughts on using PARP inhibitors and antibody-drug conjugates at the 2023 Debates and...
Ipilimumab Plus Nivolumab May Improve Outcomes in Patients With Refractory Metastatic Melanoma, Study Suggests
Researchers have discovered that ipilimumab in combination with nivolumab may be an effective second-line therapy in patients with PD-1 blockade–refractory metastatic melanoma, according to a recent study published by VanderWalde et al in Nature Medicine. These findings demonstrated the combination ...
Therapeutic Implications of DNA Repair Discoveries in Patients With Homologous Recombination Deficiencies
Long-molecule scars may help identify patients with BRCA1- and BRCA2-deficient cancer types, according to a recent study published by Setton et al in Nature. Background Once DNA is damaged by toxins, radiation, or normal cell division, human cells must continually fix DNA breaks to survive. When...
Medicaid Expansion and Participation in Cancer Clinical Trials Among Patients Insured by Medicaid
Investigators may have uncovered the impact of the 2014 and 2015 Medicaid expansion on cancer clinical trial participation, according to a recent study published by Unger et al in JAMA Oncology. The new findings suggested that Medicaid expansion under the Patient Protection and Affordable Care Act...
Does Benzo Type Impact Pancreatic Cancer Outcomes?
Pancreatic cancer has the poorest 5-year survival rate (12.5%) relative to all other cancers. In 2023, about 64,050 people will be diagnosed with pancreatic cancer, and approximately 50,550 will die of the disease. A retrospective study investigating the impact of palliative care medicine on the...
Four Novel Biomarkers May Help Detect Black Patients at Risk of Advanced Prostate Cancer
Researchers have identified a cell metabolism process found in male patients with West African ancestry who have diabetes and metastatic prostate cancer that could potentially lead to improved testing and treatments for Black patients with both diseases. The findings by Shuck et al were presented...
Diagnosing Early-Stage Bladder Cancer in Patients With Hematuria: Novel mePENK Test
Researchers have found that the new PENK methylation (mePENK) test could potentially pave the way for a breakthrough in early bladder cancer detection in patients with hematuria, according to a novel study published by Oh et al in The Journal of Molecular Diagnostics. The findings could reduce the...
Expert Point of View: Michiel S. Van der Heijden, MD, PhD
Formal discussant of the CheckMate 274 trial, Michiel S. Van der Heijden, MD, PhD, of the Netherlands Cancer Institute, said it is an “important” study. “In looking at these results, one should consider the goal of adjuvant therapy in this setting. Is overtreatment of patients cured by surgery...
Expert Point of View: Daniel P. Petrylak, MD
“Clinically, the implications [of the THOR trial] are clear in that all metastatic urothelial cancers should be tested for FGFR mutations,” stated invited discussant Daniel P. Petrylak, MD, of Yale School of Medicine. “This should be done at the beginning of treatment for metastatic disease, as it...
THOR Trial: Erdafitinib Improves Outcomes vs Chemotherapy in FGFR-Altered Advanced Urothelial Carcinoma
Targeted treatment with the fibroblast growth factor receptor (FGFR) inhibitor erdafitinib significantly improved overall survival, progression-free survival, and objective response rates compared with investigator’s choice of chemotherapy in patients with advanced urothelial cancers and FGFR2/3...
Expert Point of View: Monica Chatwal, MD
Medical oncologist Monica Chatwal, MD, of Moffitt Cancer Center, Tampa, Florida, commented on the take-home points from the ARASENS trial. “The ARASENS trial continues to show a survival benefit for a triplet therapy approach in metastatic hormone-sensitive prostate cancer with androgen-deprivation ...
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
The addition of the androgen receptor inhibitor darolutamide to androgen-deprivation therapy and docetaxel reduced the risk of death by 30% compared with androgen-deprivation therapy plus docetaxel in patients with metastatic hormone-sensitive prostate cancer, according to a post hoc analysis of...
Expert Point of View: Oliver Sartor, MD
The results of recent trials of PARP (poly [ADP-ribose] polymerase) inhibitor plus second-generation androgen receptor inhibitor combinations have had varying results in metastatic castration-resistant prostate cancer. Some trials suggest the benefit is confined to those with BRCA mutations and/or...
Expert Point of View: David A. Braun, MD, PhD
David A. Braun, MD, PhD, of Yale Cancer Center, was the formal discussant of the abstract on the 4-year follow-up of the CLEAR trial. “We have made remarkable progress [in advanced renal cell carcinoma] and are now in the combination era of immunotherapy-based therapy and immunotherapy-based...
CLEAR Trial: Continued Survival Benefit With First-Line Lenvatinib Plus Pembrolizumab in Advanced Kidney Cancer
At extended follow-up, lenvatinib plus pembrolizumab showed sustained superiority over sunitinib for overall and progression-free survival as first-line treatment for advanced renal cell carcinoma.1 The majority of the benefit was observed in intermediate- and poor-risk subgroups, according to the...
Genitourinary Oncology 2023 Almanac
It is an exciting time in the development of new treatments for urologic cancers. There have been a number of major changes both in advanced disease and in the perioperative setting over the past year. Urothelial and Bladder Cancers In urothelial cancer, at last, we have randomized data supporting...
Expert Point of View: Ajay K. Nooka, MD, MPH
Insights on findings from the phase II MonumenTAL-1 trial1 were offered by Ajay K. Nooka, MD, MPH, Professor in the Department of Hematology and Medical Oncology, and Medical Director of the Winship Data and Technology Applications Shared Resource, Winship Cancer Institute, Emory University School ...
Study Shows Activity of Talquetamab in Highly Refractory Multiple Myeloma
In the phase I/II MonumenTAL-1 trial, the novel bispecific antibody talquetamab produced responses in more than 70% of heavily pretreated patients with multiple myeloma.1 Of note, the safety profile confirmed results of the phase I portion of the study (recently published in TheNew England Journal...
Expert Point of View: Urvi A. Shah, MD
Urvi A. Shah, MD, Assistant Attending at Memorial Sloan Kettering Cancer Center and Assistant Professor at Weill Cornell Medicine, New York, moderated the session where the MagnetisMM trial updates1,2 were reported and was interviewed by The ASCO Post. Elranatamab vs Teclistamab Dr. Shah noted...
Expert Point of View: Ciara L. Freeman, MD, PhD and Asher Chanan-Khan, MD
Ciara L. Freeman, MD, PhD, Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, was impressed with the CARTITUDE-4 findings. She said “treaters and patients” will be “watching this space” to see how the results change the...
Expert Point of View: Alexey Danilov, MD, PhD
Alexey Danilov, MD, PhD, Co-Director, Toni Stephenson Lymphoma Center and Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California, commented on the phase III ALPINE trial comparing ibrutinib and zanubrutinib in patients...
Is Zanubrutinib Poised to Become a New Standard of Care in Relapsed or Refractory CLL and SLL?
The next-generation Bruton’s tyrosine kinase (BTK) inhibitor zanubrutinib demonstrated superior progression-free survival compared with ibrutinib, with an improved cardiac safety profile, in the first head-to-head comparison between these two BTK inhibitors in relapsed or refractory chronic...
Expert Point of View: Joseph C. Alvarnas, MD
“Pediatric acute lymphoblastic leukemia (ALL) is the paradigmatic success story in hematology,” said Joseph C. Alvarnas, MD, Professor in the Department of Hematology and Hematopoietic Cell Transplant, Vice President of Government Affairs, and Chief Clinical Advisor for AccessHope at City of Hope...
Expert Point of View: Catherine S. Diefenbach, MD
Catherine S. Diefenbach, MD, Associate Professor at NYU Grossman School of Medicine, Director of the Clinical Lymphoma Program, and Director of Hematology Translational Research at Perlmutter Cancer Center, in New York, called the findings from the TRANSFORM trial “very striking.” “This study...
MAGNOLIA Trial: Zanubrutinib Yields High Response Rates With Low Rate of Cardiac Events in Marginal Zone Lymphoma
Zanubrutinib—a next-generation Bruton’s tyrosine kinase (BTK) inhibitor—achieved high response rates and durable disease control with a low incidence of cardiac effects in patients with relapsed or refractory marginal zone lymphoma, according to updated findings from the final analysis of the phase ...
SWOG S1826: Nivolumab Plus AVD Surpasses Standard-of-Care Combination Regimen in Patients With Advanced Hodgkin Lymphoma
The addition of nivolumab, an immune checkpoint inhibitor, to chemotherapy significantly improved progression-free survival in adults and children with advanced classical Hodgkin lymphoma with reduced toxicity compared with standard-of-care brentuximab vedotin plus chemotherapy, according to the...
